AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17692728
Drug: Suspension formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension formulation of acyclovir 400 mg
Trial: 17692728
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of acyclovir 400 mg
Trial: 14757326
Drug: CRH(1)-receptor-antagonist R121919
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH(1)-receptor-antagonist R121919 (higher doses)
Trial: 14757326
Drug: CRH(1)-receptor-antagonist R121919
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH(1)-receptor-antagonist R121919 (lower doses)
Trial: 14757326
Drug: CRH(1)-receptor-antagonist R121919
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH(1)-receptor-antagonist R121919
Trial: 9709744
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (standard intensity)
Trial: 9709744
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (less than standard intensity)
Trial: 3135010
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment for women
Trial: 29407665
Drug: L'/L' homozygotes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L'/L' homozygotes
Trial: 26754071
Drug: FENIX magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FENIX magnetic sphincter augmentation (MSA)
Trial: 19878097
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (CT group)
Trial: 9609409
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen intravenously (i.v.)
Trial: 30676200
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (infusion resulting in an arterial blood alcohol concentration of 80 mg%)
Trial: 30676200
Drug: Placebo condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo condition (saline infusion)
Trial: 25873213
Drug: Bevacizumab (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (standard dose, monthly review)
Trial: 25873213
Drug: Bevacizumab (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (low dose, monthly review)
Trial: 25873213
Drug: Bevacizumab (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (standard dose, two-monthly review)
Trial: 25873213
Drug: Bevacizumab (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (low dose, two-monthly review)
Trial: 23001556
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg, increased to 70 mg over 4 weeks and maintained for another 4 weeks
Trial: 21425570
Drug: Integrative medical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative medical therapy (Chinese drugs)
Trial: 21425570
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic therapy only)
Trial: 19178385
Drug: Endurance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance exercise (thrice weekly 45‐min intervals)
Trial: 19178385
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (three 45‐min episodes of stretching, balance training and coordination)
Trial: 16172624
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 5 g of creatine monohydrate daily for 6 days)
Trial: 16172624
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, daily for 6 days)
Trial: 14520721
Drug: Long-acting β2-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-adrenoceptor agonists (LABAs)
Trial: 14520721
Drug: Long-acting β2-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-adrenoceptor agonists (LABAs) with regular maintenance with inhaled corticosteroids (ICS)
Trial: 10944595
Drug: Adjuvant CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CMF chemotherapy (given to 77 patients, 65%)
Trial: 8349935
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg intranasal)
Trial: 28822559
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics (7 days of oral metronidazole and ciprofloxacin)
Trial: 28822559
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care without antibiotics
Trial: 24714011
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 μg plus 3 ml of 0.5% hyperbaric bupivacaine (Group FB)
Trial: 24714011
Drug: Intrathecal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal tramadol 25 mg plus 3 ml of 0.5% hyperbaric bupivacaine (Group TB)
Trial: 24714011
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline plus 3 ml of 0.5% hyperbaric bupivacaine (Group SB)
Trial: 19740393
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg alone
Trial: 19740393
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg with omeprazole 40 mg (administered 15 min before imatinib on day 5)
Trial: 19740393
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg with omeprazole 40 mg
Trial: 14692022
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of Zoledronic acid (Zol)
Trial: 14692022
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of Pamidronate (Pam)
Trial: 11207631
Drug: Testosterone with
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone with 10 mg oestradiol (group 2, n = 7)
Trial: 11207631
Drug: Testosterone with
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone with 20 mg oestradiol (group 3, n = 6)
Trial: 2720925
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus gamma-globulin, 400 mg/kg/day for 4 consecutive days (n = 28, 60%)
Trial: 2720925
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n = 19, 40%)
Trial: 28945641
Drug: 4-week finger
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week finger grip training program (suspensions on small holds, 2 times a week)
Trial: 15056989
Drug: Exercise Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Group (EG) - 1 hour of physical exercise twice a week for 5 months
Trial: 15523434
Drug: Oil-based oral
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-based oral spray
Trial: 15523434
Drug: Water-based oral
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based oral spray (placebo)
Trial: 8747042
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (0.5 mg/day s.c.)
Trial: 8747042
Drug: Low-dose leuprolide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leuprolide acetate depot (1.88 mg s.c.)
Trial: 21868743
Drug: Androgen replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen replacement therapy, aerobic physical activity, tadalafil administration
Trial: 20200926
Drug: ALN 5
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 5 mg/day
Trial: 10341016
Drug: ALN 10
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 10 mg/day
Trial: 16286100
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg daily)
Trial: 16230122
Drug: Corticosteroid (deflazacort,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (deflazacort, 30 mg daily) plus tamsulosin
Trial: 7756099
Drug: Intravenous frusemide:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide: 40 mg bolus then 40 mg h‐1 for 3 h
Trial: 7756099
Drug: Captopril: two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril: two 12.5 mg oral doses separated by 2 h
Trial: 7756099
Drug: Combined dosing:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dosing: first captopril dose preceded the frusemide bolus by 30 min
Trial: 26786987
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen therapy with Venturi mask for first 12 hours of admission
Trial: 16970537
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with tea catechin extract solution (200 microg/mL catechins, 60% epigallocatechin gallate), performed three times daily for 3 months.
Trial: 16970537
Drug: Gargling without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gargling without tea catechin extracts (control group), performed three times daily for 3 months.
Trial: 26552175
Drug: OMT low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT low dose (1.89 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Trial: 26552175
Drug: OMT medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT medium dose (3.78 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Trial: 26552175
Drug: OMT high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT high dose (7.56 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Trial: 26552175
Drug: SB203580 (p38MAPK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB203580 (p38MAPK blocking agent, 1 x 10(‐5) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Trial: 26552175
Drug: Model group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model group (20 μg x L(‐1) TGF‐β1)
Trial: 22042952
Drug: 3 or
RxNorm normalized name: Cytra-3 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 4 months of androgen suppression therapy (AST)
Trial: 10905240
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice daily for 7 days)
Trial: 8730248
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg at 07.30 h (early evening)
Trial: 8730248
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg at 22.00 h (bedtime)
Trial: 1417177
Drug: r‐hGH (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hGH (0.1 mg/kg/day or 0.2 mg/kg/day) + insulin (1 mU/kg/minute)
Trial: 1417177
Drug: insulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin (1 mU/kg/minute)
Trial: 31923070
Drug: Opioid use
RxNorm normalized name: Modia Opioid Use Disorder Support Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid use disorder treatment
Trial: 25786714
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol 0.05% applied at night
Trial: 25786714
Drug: Systemic mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic mycophenolate mofetil (MMF) 2 g/day
Trial: 20472399
Drug: LPD 7/7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPD 7/7 (low protein diet providing 0.8 g/kg per day, 7 days a week)
Trial: 20472399
Drug: LPD 6/7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPD 6/7 (low protein diet providing 0.8 g/kg per day, 6 days a week)
Trial: 15231567
Drug: Brief anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief anthracycline-based chemotherapy plus high-dose extended irradiation
Trial: 11300386
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, bolus of 0.05 ml/kg, lockout interval of 10 min, total dose limit of three bolus doses per hour.
Trial: 11300386
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (EPI) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, continuous infusion of 0.1 ml kg(‐1) h(‐1) and a minimal extra bolus dose of 0.2 ml with the same lockout interval.
Trial: 9129064
Drug: zalcitabine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zalcitabine (0.03 mg/kg/day) in combination with zidovudine (720 mg/m2/day)
Trial: 3203716
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg oral dose in the fasted state
Trial: 3203716
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg oral dose with a standard breakfast
Trial: 3203716
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg oral dose in the fed state
Trial: 3203716
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg oral dose in both states
Trial: 31743987
Drug: Corticosteroid (COR)
RxNorm normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid (COR) injection
Trial: 31743987
Drug: Prolotherapy (PRO)
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy (PRO) injection
Trial: 21254641
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial treatment plus immunotropic drug (lavomax) 1.25 g
Trial: 21254641
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial treatment
Trial: 12639206
Drug: Dehydroepiandrosterone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydroepiandrosterone (50 mg/d)
Trial: 11095459
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (fenfluramine, 60 mg/day) coupled with an energy-restricted diet (−2930 kJ/day)
Trial: 11095459
Drug: High-insulin individuals
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-insulin individuals
Trial: 29490294
Drug: Furosemide (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (60-120 mg/day, intravenously) for 1 week
Trial: 29490294
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no furosemide or other diuretics)
Trial: 25268730
Drug: Rhodiola rosea
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea (364 mg daily for 42 days)
Trial: 25268730
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsule daily for 42 days)
Trial: 22977989
Drug: Spray product
RxNorm normalized name: Oral Spray Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray product
Trial: 18689370
Drug: Bread fortified
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread fortified with 138 µg folic acid and 9.6 µg vitamin B-12 daily
Trial: 16199244
Drug: Muraglitazar 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muraglitazar 2.5 mg
Trial: 16199244
Drug: Muraglitazar 5
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muraglitazar 5 mg
Trial: 16199244
Drug: Muraglitazar 5
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muraglitazar 5 mg (open-label cohort)
Trial: 10586004
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine with pa vaccine
Trial: 10586004
Drug: dTpa and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dTpa and pa vaccines
Trial: 8915665
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (300 mg/day, at bedtime)
Trial: 8915665
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone (300 mg/day)
Trial: 1888621
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel (1 g diclofenac/100 g, 80 mg three times daily)
Trial: 1888621
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel and Placebo gel
Trial: 3936085
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg dextroamphetamine sulfate
Trial: 28599060
Drug: Sacubitril/valsartan 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 400 mg once daily for 5 days
Trial: 22676908
Drug: Endoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic surgery for hematoma evacuation and the best medical treatment
Trial: 22676908
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (the best medical treatment)
Trial: 15830639
Drug: SRP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP and 14% doxycycline gel (DOX)
Trial: 15830639
Drug: SRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP with subgingival placebo gel (VEH)
Trial: 11852170
Drug: Inactivated Influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Influenza Vaccine
Trial: 2910293
Drug: Retrobulbar injections
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retrobulbar injections (5 mL)
Trial: 2910293
Drug: Periocular injections
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injections (5 mL)
Trial: 28873284
Drug: Ultrasound-guided PRP
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided PRP injection
Trial: 28749177
Drug: Systolic blood
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic blood pressure treatment target of 120 mmHg
Trial: 28749177
Drug: Systolic blood
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic blood pressure treatment target of 120 mmHg in the lowest tertile of baseline systolic blood pressure
Trial: 28749177
Drug: Systolic blood
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic blood pressure treatment target of 140 mmHg
Trial: 21435016
Drug: Cresco components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cresco components loaded 10 days post-implant placement
Trial: 21435016
Drug: Cresco components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cresco components loaded 6-8 weeks post-implant placement
Trial: 21435016
Drug: Conventional components
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional components loaded 6-8 weeks post-implant placement
Trial: 10919344
Drug: Flucozole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucozole (200 mg)
Trial: 10919344
Drug: Diflucan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucan (200 mg)